Adenovirus-mediated shRNA interference against HSV-1 replication in vitro

Area of Science:

• Virology
• Molecular Biology
• Gene Therapy

Background:

• Herpes simplex virus type 1 (HSV-1) UL29 and UL28 proteins are essential for viral replication and packaging.
• RNA interference (RNAi) strategies targeting these genes show promise for antiviral development.
• Adenovirus type 5 (Adv5) vectors offer a method for delivering therapeutic RNA molecules.

Purpose of the Study:

• To evaluate the efficacy of short hairpin RNAs (shRNAs) targeting HSV-1 UL29 and UL28 genes delivered by Adv5 vectors.
• To assess the antiviral activity of these shRNAs against HSV-1 replication in vitro.
• To investigate the potential synergistic effects and duration of antiviral action.

Main Methods:

• Chemically synthesized shRNAs targeting HSV-1 UL29 and UL28 genes.
• Delivery of shRNAs into Vero cells using a replication-defective Adv5 vector.
• Inhibition of HSV-1 replication measured by viral RNA, protein synthesis, and progeny virus production.
• Assessment of antiviral effects at different time points relative to HSV-1 challenge.

Main Results:

• Adv5-delivered shRNAs targeting UL29 and UL28 significantly suppressed HSV-1 replication in vitro.
• A synergistic antiviral effect was observed when Ad-UL28shRNA and Ad-UL29shRNA were combined.
• Antiviral effects were sustained for at least 4 days and effective even when administered prophylactically 12 hours before HSV-1 inoculation.
• Comparable antiviral activities were demonstrated for shRNAs targeting either UL29 or UL28.

Conclusions:

• Adv5-mediated delivery of shRNAs targeting HSV-1 UL29 or UL28 demonstrates significant in vitro antiviral activity.
• Combined targeting of UL29 and UL28 exhibits synergistic effects, enhancing viral suppression.
• This approach represents a potential alternative strategy for controlling HSV-1 infections.